Lark­spur Bio­sciences kicks off with $30M+, hunt­ing for new on­col­o­gy im­munother­a­pies

Based in Mass­a­chu­setts, Lark­spur Bio­sciences, a biotech fo­cused on de­vel­op­ing new im­muno-on­col­o­gy treat­ments, is now armed with $35.5 mil­lion in com­bined seed/Se­ries A back­ing.

The round, led by the Po­laris In­no­va­tion Fund, 3E Bioven­tures Cap­i­tal and Take­da’s VC arm, will help fund de­vel­op­ment of new ther­a­pies for col­orec­tal can­cer.

Lark­spur CEO Cather­ine Sabatos-Pey­ton, a for­mer ex­ec di­rec­tor at No­var­tis In­sti­tutes for Bio­Med­ical Re­search, has been run­ning the com­pa­ny in stealth mode since No­vem­ber. She told End­points News that she got in­volved with Lark­spur in 2021, orig­i­nal­ly as the chief sci­ence of­fi­cer. Sabatos-Pey­ton did her PhD un­der the tute­lage of Vi­jay Kuchroo, one of the co-founders of Lark­spur, while at Har­vard Uni­ver­si­ty study­ing au­toim­mu­ni­ty.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN